Stockreport

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus ery [Read more]